Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.
Provider: S&P Capital IQ – STARS Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Galapagos NV and AbbVie Inc Enter into Global to Collaborate on Potentiator and Combination Therapies in Cystic Fibrosis

Tuesday, 24 Sep 2013 08:01am EDT 

Galapagos NV and AbbVie Inc announced that they have entered into a global alliance to discover, develop and commercialize new potentiator and combination therapies in cystic fibrosis (CF), an inherited chronic disease that affects 70,000 people worldwide. The Companies will work collaboratively to contribute technologies and resources in order to develop and commercialize oral drugs that address the main mutations in CF patients, including F508del and G551D. The goal of the collaboration is to identify compounds that correct defects in expression of (corrector) and/or increase the activity (potentiator) of the main mutations in the cystic fibrosis transmembrane regulator (CFTR) protein, including the F508del mutation. In the alliance, AbbVie Inc and Galapagos NV will develop potentiators and correctors discovered by Galapagos NV and expand the range of molecules, with the aim to initiate Phase 1 clinical studies at the end of 2014. Following clinical development and regulatory approval, AbbVie Inc will be responsible for commercial activities, with Galapagos NV retaining exclusive rights in China and South Korea and co-promotion rights in Belgium, the Netherlands, and Luxembourg. Under the terms of the agreement, AbbVie Inc will make an initial upfront payment of USD 45 million to Galapagos NV for rights related to the global alliance. 

Company Quote

0.01 +0.01%
30 Jun 2015